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RNA  interference  (RNAi)  is  a  process  in  which  small 
non-coding RNAs (of endogenous or exogenous origin) 
are  incorporated  into  a  multi-protein  RNA-induced 
silencing complex (RISC) in cells to silence the expression 
of a sequence-homologous target RNA [1]. Three major 
types of small non-coding RNAs function as RNAi: the 
piRNAs (PIWI-interacting RNAs), miRNAs (microRNAs), 
and  siRNAs  (small  interfering  RNAs).  piRNAs  and 
miRNAs are endogenous, small non-coding RNAs trans-
cribed from cellular loci and then processed to generate 
fragments  that  engage  with  the  downstream  silencing 
machinery.  Until  recently,  siRNAs  were  thought  to  be 
exclusively processed from the exogenous RNA of patho-
gens (for example, viruses) that infect the cell, but that 
view changed with the discovery of abundantly expressed 
endogenous siRNAs (endo-siRNAs) in animal cells [2,3]. 
Currently,  mammals  are  known  to  have  hundreds  of 
thousands  of  different  piRNAs,  produced  from  gene 
clusters  of  repetitive  elements,  and  more  than  1,000 
different  miRNAs;  the  number  of  endo-siRNAs  still 
needs to be fully clarified.
Simplified  representations  of  the  different  RISC 
complexes are shown schematically in Figure 1. miRNA 
biogenesis requires the RNAse III proteins Drosha and 
Dicer, while siRNA processing depends solely on Dicer, 
and  the  nuclease(s)  required  for  piRNA  processing 
remain(s) unidentified [4]. Short double-stranded RNAs 
(dsRNAs) are bound to form the miRNA- and siRNA-
RISC complex while the biogenesis of the piRNA-RISC 
can arise from either a single-stranded precursor RNA or 
through a ‘ping-pong’ mechanism [1]. A major constitu  ent 
of the miRNA-RISC and siRNA-RISC complexes is the 
AGO protein; the parallel constituent in piRNA-RISC is 
the  PIWI  protein.  In  the  RISC  complex,  a  guide  RNA 
strand  is  retained  that  captures  target  mRNA  through 
complete or incomplete sequence complementarity. The 
RISC complex then may either inhibit translation of the 
mRNA  or,  through  the  so-called  slicer  activity  of  the 
AGO and PIWI proteins, degrade it, thus silencing the 
gene from which it was transcribed.
One of the earliest descriptions of RNAi was in Caeno­
rhabditis elegans. Early on, it was found that mutations 
affecting  RNAi  function  in  C.  elegans  and  Drosophila 
melanogaster  produced  apparently  normal  organ  isms, 
but that these mutations increased the susceptibility of 
mutated  animals  to  infection  by  viruses  [5,6].  These 
findings suggested an evolutionary role for RNAi in the 
defense  of  cells  against  pathogenic  viral  infections. 
Indeed, this rationale is consistent with the role of RNAi 
in post-transcriptional gene silencing of plant viruses [7] 
and  with  the  conservation  of  an  RNAi-like  antiviral 
defense  mechanism  using  small  CRISPR  (clusters  of 
regularly interspaced short palindromic repeats) RNAs in 
prokaryotes  [8].  The  need  for  conservation  of  an 
analogous antiviral system in vertebrates, however, has 
been  questioned  on  the  grounds  of  their  advanced 
adaptive immunity to viral (and non-viral) pathogens and 
on the emergence of an interferon-based defense mecha-
nism. Silencing mechanisms that depend on RNAi are, 
however,  already  known  to  operate  in  vertebrates  to 
protect the germline DNA from transposons and endo-
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also to operate in somatic cells.
RNAi	and	regulation	of	retroelements		
and	viruses
Non-virologists are often surprised to learn that nearly 
50%  of  the  human  genome  is  made  up  of  virus-like 
transposable  elements  (TEs)  [9],  which  are  composed 
mostly  of  retrotransposons  replicated  through  reverse 
transcription, and DNA transposons propagated through 
a cut-and-paste mechanism. Included among the TEs in 
the mouse and human genomes are distinctly recog  ni-
zable  endogenous  retroviruses  (ERVs;  integrated  retro-
virus sequences that have entered the germline), with 5 
to  8%  of  human  DNA  estimated  to  consist  of  human 
endogenous retrovirus (HERV) elements that segregate 
into 26 phylogenetically distinct retroviral lineages [10]. 
These  ERVs  are  likely  to  be  fossilized  remnants  of 
anciently  endogenized  virus  infections.  While  active 
human  ERVs  are  rare  [11],  human  non-ERV  TEs  (for 
example, short interspersed elements - SINES - and long 
interspersed elements - LINES) remain active for trans-
position, accounting for 1 new insertion every 100 to 200 
human births or roughly 1 in every 1,000 human genetic 
mutations [12]. By contrast, mouse ERVs are numerous 
and highly active and cause approximately 10% of spon-
taneous mutations in inbred mice [13].
Active  replication  of  ERVs  and  virus-like  elements 
needs  to  be  suppressed  in  the  germ  line  because  they 
cause  novel  deleterious  germline  mutations.  In  mouse 
germ cells, piRNA-mediated silencing has been shown to 
be  important for  repressing  TE  activity  [14].  However, 
ERV and retrotransposon activities are not limited to the 
germline; they also occur in somatic cells where they can 
induce disease, in particular ERV- and retrotransposition-
associated  cancers  [15,16].  This  raises  the  question  of 
whether  mechanisms  also  exist  to  protect  somatic 
tissues. There is evidence for two such mechanisms. First, 
somatic cell endo-siRNAs, as recently described, may act 
to  control  ERV  and  TE  activity  [3].  Second,  emerging 
data  have  unexpectedly  revealed  that  piRNAs  are  not 
confined to germline cells, but are also abundant in the 
somatic tissues of fruitfly, mouse, and rhesus macaques 
[17], in the neurons of Aplysia [18], and in a human T cell 
line [19]. PIWI mRNA and MIWI protein have also been 
detected in macaque and mouse somatic tissues [17]. If 
these  new  discoveries  are  confirmed,  then  ERV/TE-
suppression  in  somatic  cells  may  be  mediated  by 
piRNA-RISC.
Figure 1. miRNA-, siRNA-, piRNA-RISC complexes effect complementarity-driven silencing of targeted mRNAs.	Small miRNAs, siRNAs, 
or piRNAs (red) serve as guide sequences within the RNA-induced silencing complex (RISC) to capture target mRNA via incomplete (miRNA) or 
complete (siRNA, piRNA) base-pairing. The expression of the targeted mRNA is silenced either by RNA degradation or by inhibition of translation.
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in regulating viral infections in mammalian cells. As in 
the early studies that showed RNAi pathway mutations in 
C. elegans and D. melanogaster increased these organisms’ 
susceptibility to infection by viruses [5,6], mutations in or 
perturbation  of  RNAi  pathway  components  in  mouse 
[20], monkey cells [21] or human cells [22,23] increase 
the  replication  of  vesicular  stomatitis  virus  (VSV), 
influenza  A  virus,  and  human  immunodeficiency  virus 
(HIV-1), respectively.
miRNA-mediated	regulation	of	viral	infection
The human genome encodes more than 1,000 different 
miRNAs;  these  miRNAs  and  their  miRNA-RISC  com-
plexes  recognize  RNA  targets  through  imperfect  base-
pairing [1]. In silico analyses based on complementarity 
of miRNAs and their putative mRNA targets have led to 
estimates  that  miRNAs  may  regulate  up  to  30%  of 
protein-coding  human  mRNAs.  Not  surprisingly,  early 
analyses of the more than 1,000 human miRNA sequences 
aligned against a large dataset of pathogenic mammalian 
viral genomes indicated that most, if not all, viruses are 
recognized by one or more cellular miRNAs [24].
Numerous studies now report the direct regulation of 
mammalian  viruses  by  host  miRNAs  (Figure  2).  Thus, 
human  liver-specific  miR-122  has  been  shown  to 
functionally augment hepatitis C virus (HCV) replication 
[25],  while  more  than  half  a  dozen  human  miRNAs, 
including miR-199a-3p, miR-210, and miR-125a-5p, are 
found to repress hepatitis B virus (HBV) replication [26]. 
Other examples include miR-323, miR-491, and miR-654 
targeting influenza virus, miR-27 and miR-93 targeting 
VSV, and miR-28, miR29a, miR-125b, miR-150, miR-223, 
and  miR-382  targeting  HIV-1  [27].  More  recent  data 
suggest  that  herpes  viruses  (for  example,  Epstein  Barr 
virus (EBV) and Kaposi’s sarcoma herpes virus (KSHV)) 
are  targeted  by  several  cellular  miRNAs,  including  the 
miR-17/92 and miR-106b/25 clusters [28-30], coxsackie 
virus  is  targeted  by  miR-342-5p  [31],  and  human 
papilloma  virus  (HPV)  is  targeted  by  several  cellular 
miRNAs [32]. The list of cellular miRNAs implicated in 
regulating  mammalian  viruses  promises  to  grow  much 
longer. Indeed, in a survey of more than 25,000 individual 
HCV, HIV-1, HPV and HBV sequences, it was found that 
there is strong conservation and preservation of cellular 
miRNA-targeted  sites  within  those  viruses,  prompting 
the  authors  to  conclude  that  ‘human  microRNAs 
effectively  contribute  to  the  host  defense  by  targeting 
essential  viral  genes,  thereby  reducing  the  replication 
efficiency of the virus’ [33]. Taken together, the accumu-
lated findings support the concept that ambient miRNAs 
expressed in host cells represent a first layer of bioactive 
encounters that form a part of the cell’s overall antiviral 
arsenal.
Efficient	processing	of	viral	short	hairpin	RNAs	and	
miRNAs	occurs	in	mammalian	cells
Despite  the  above  findings,  there  remains  some  con-
tention  about  the  physiological  function  of  RNAi  in 
regulating viruses in mammalian cells. This contention 
may  be  caused  in  part  by  expectations  of  mammalian 
cells/mammalian  viruses  based  on  results  from 
invertebrate  cells/invertebrate  viruses.  For  instance, 
when  invertebrate  viruses  infect  mosquito  cells,  the 
incoming viral dsRNAs or replication intermediates are 
frequently processed into small exogenous siRNAs (exo-
siRNAs)  [34].  By  contrast,  when  mammalian  viruses, 
such  as  HIV-1,  infect  human  cells,  the  production  of 
processed  viral  exo-siRNAs  is  rare  [19,35].  Some  have 
interpreted these results to mean that invertebrate cells 
sense  and  process  viral  dsRNAs  and  then  deploy  exo-
siRNAs  in  antiviral  RISC  complexes  while  vertebrate 
(mammalian) cells cannot perform these functions. This 
interpretation however is challenged by experiments in 
which  an  authentic  short  hairpin  RNA  (shRNA)  was 
engineered  into  the  HIV-1  genome  and  the  genome 
introduced  into  human  cells,  with  ensuing  efficient 
siRNA production from the ‘viral-shRNA’ [36]. Moreover, 
a version of the above experiment is performed hundreds, 
if not thousands, of times every day by investigators who 
use  shRNA  libraries  cloned  into  lentivirus  vectors  to 
transduce  human  cells  for  the  purpose  of  silencing 
specific  target  genes.  In  every  instance,  the  lentivirus-
shRNA  is  recognized  and  processed  by  human  cells 
faithfully into the expected siRNA (Figure 2).
How then does one reconcile the above observations? 
One possibility is that human (mammalian) cells, rather 
than  being  unable  to  efficiently  recognize  and  process 
viral dsRNAs or shRNAs into siRNAs, may actually be 
more proficient than invertebrate cells at processing and 
using  siRNAs  in  antiviral  RISC  complexes  against 
invading viruses. In this case, RNA viruses with double-
stranded shRNA-like sequences amenable for processing 
into siRNAs might be subject to more potent negative 
selection in human than in invertebrate cells. Over time, 
strong  stringent  selection  in  mammalian  cells  (and 
relaxed  selection  in  invertebrate  cells)  would  result  in 
many  human  viruses  being  devoid  of  shRNA-like  or 
dsRNA  sequences,  while  the  less  robustly  restricted 
inver  tebrate  viruses  would  still  keep  shRNA  and/or 
dsRNA sequences. Hence, today’s human cells would face 
many viruses largely lacking shRNA/dsRNA sequences, 
accounting, in part, for the rarity with which viral exo-
siRNAs are detected in mammalian infections (see, for 
example,  [37]).  On  the  other  hand,  invertebrate  cells 
would still encounter many viruses that harbor shRNA 
sequences,  and  consequently  viral  exo-siRNAs  would 
more frequently be found in infected invertebrate cells 
[34]. In short, the argument is that human cells do, in 
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siRNA-RISC as an antiviral defense, but the rarity of this 
process in human cells may be because many mammalian 
viruses have already been tightly selected by human cells 
not to maintain siRNA-producing sequences.
They do, however, encode miRNA sequences [38,39]. 
These viral miRNAs are processed efficiently in human 
cells, are engaged in miRNA-RISCs, and are frequently 
used by the cell (or the virus) to target other viral trans-
cripts. Examples of this type of usage include the human 
cytomegalovirus (CMV) miR-112-1 targeting the CMV 
IE1 viral RNA [40], the EBV BART miRNAs targeting the 
EBV LMP mRNAs [41,42], and the HSV miR-H2, miR-
H3,  and  miR-H4  targeting  viral  ICP0  and  ICP34.5 
mRNAs [43]. Similar miRNA-mRNA targeting can also 
occur  in  the  case  of  a  model  retroviral  infection  [44]. 
Taken  together,  these  findings  support  the  view  that 
mammalian  cells  employ  viral  exo-miRNA-RISCs  to 
regulate  viral  infections,  paralleling  invertebrate  and 
plant  cells  that  use  viral  exo-siRNA-RISCs  to  regulate 
their cognate viruses (Figure 2).
Outstanding	questions	and	future	perspectives
The above arguments apply to retroviruses and herpes 
viruses, which have been extensively studied for RNAi 
generation. What remains unaddressed is the processing 
of the many plus-sense, minus-sense, and human dsRNA 
viruses. These viruses present fully dsRNA substrates as 
part of their genomes or as replication intermediates. To 
date, they have not been extensively investigated for the 
biogenesis of viral non-coding RNAs, and future findings 
from these viruses could yield important insights.
Several aspects of the RNAi-virus-host cell interaction 
also  merit  closer  scrutiny.  One  issue  is  whether  the 
expression  of  endo-siRNAs  in  mammals  is  similar 
between germline tissues and somatic tissues. The data 
for somatic tissues are currently incomplete. The emerg-
ing finding that piRNAs are present in both germ and 
somatic cells raises the possibility that endo-siRNAs con-
form to an analogous pattern.
A  second  issue  is  the  dynamic  strike-counterstrike 
interplay between cells in which RNAi serves to combat 
viruses and viruses evade RNAi to successfully replicate 
in  cells  [45].  One  view  is  that  efficiently  replicating 
viruses  must  encode  RNAi  suppressors.  Indeed,  while 
many  mammalian  viruses  do  apparently  have  RNAi 
suppressor moieties [27], an RNAi suppressor function is 
only one of several means (for example, shielding of the 
virus genome from RNAi, sequence changes in the viral 
genome  to  evade  RNAi,  virus  modulation  of  cellular 
miRNA  expression,  and  virus  adaptation  to  cellular 
RNAi) [38] at the virus’ disposal to skirt cellular RNAi 
restriction. Indeed, shielding of the viral RNA genome 
from  RNAi  [46],  changes  in  viral  sequences  to  evade 
RNAi  [47],  and  virus-modulation  of  cellular  miRNA-
expression  [48-50)  have  all  been  reported  for  HIV-1. 
Viruses such as HIV-1 that are highly mutable may evade 
RNAi efficiently through target sequence changes; these 
Figure 2. Several ways that RNAi can regulate viruses in mammalian cells. Left: cell-endogenous endo-miRNAs are engaged in RISC complexes 
to target partially homologous viral transcripts. Middle: virus-encoded miRNA can be processed as exo-miRNAs that are engaged with RISC for 
interaction with other viral RNAs. Right: viruses that contain shRNA sequences (for example, lentiviral shRNA libraries) are processed into exo-siRNAs. 
The double-stranded RNAs (hairpins) are processed in the RISC into single-stranded guide RNAs that bind to complementary sequences in the 
mRNA, thus recruiting RISC, which degrades the mRNA or inhibits its translation. Transposable elements and endogenous retroviruses produce 
endo-siRNAs in mammalian cells. Both exo-siRNAs and endo-siRNAs can be incorporated into RISC complexes in mammalian cells to silence 
homologous target RNAs. Multiple transcripts (blue) are indicative of differently spliced RNAs.
endo-miRISC exo-miRISC exo-siRISC
transcription transcription transcription
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if at all [53]. On the other hand, less mutable viruses may 
require  strong  RNAi  suppressors  to  mitigate  RNAi 
restriction in order to replicate optimally.
A  final  issue  is  the  increasingly  convincing  new 
evidence for the existence of natural antisense transcripts 
in  human  T-lymphotropic  virus  (HTLV)-1  and  HIV-1 
[54-58]. Inside cells, these antisense viral RNAs can, in 
principle, form long RNA duplexes with their comple-
men  tary sense transcripts. The fate of these dsRNAs and 
what new functions they may provide promise to keep 
virologists busy for the next several years.
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